NCT05353166View on ClinicalTrials.gov

REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

June 2, 2025

Study Completion Date

June 2, 2025

Conditions
Heart Failure
Interventions
DRUG

REGN5381

Single dose administered via IV infusion

DRUG

Matching Placebo

Single dose administered via IV infusion

Trial Locations (1)

2025

ARENSIA Exploratory Medicine at the Republican Clinical Hospital, Chisinau

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY